DART provides a novel solution to AE reporting challenges faced by aging and serious illness researchers. While its design centers on seriously ill older adults, DART can likely be applied to research in any population and intervention type not regulated by the FDA. Future pilot testing will inform implementation.
Lubetsky et al. (Thu,) studied this question.